ICT-107: Revision history

From Glioblastoma Treatments
Jump to navigationJump to search

Diff selection: Mark the radio buttons of the revisions to compare and hit enter or the button at the bottom.
Legend: (cur) = difference with latest revision, (prev) = difference with preceding revision, m = minor edit.

12 November 2024

31 March 2024

  • curprev 14:1614:16, 31 March 2024‎ Lazy talk contribs‎ 7,141 bytes +44‎ No edit summary
  • curprev 13:1013:10, 31 March 2024‎ Lazy talk contribs‎ 7,097 bytes +7,097‎ Created page with "{{TreatmentInfo |drug_name=ICT-107 (Tumor-associated Antigen Vaccine) |FDA_approval=Still in clinical trials; not yet FDA-approved |used_for=Newly diagnosed and recurrent Glioblastoma Multiforme (GBM) |clinical_trial_phase=Phase III |common_side_effects=Reported side effects are minimal, including potential site reactions and flu-like symptoms. Few serious adverse events related to the vaccine have been reported. |OS_without=Median overall survival for GBM typically rang..."
Retrieved from "http://glioblastomatreatments.wiki:80/index.php?title=ICT-107"